Can you take Amoxil with Amphotericin b?

amphotericin B has a moderate potential interaction with Anemia.

Intravenous amphotericin B therapy may depress erythropoietin and red blood cell production and commonly causes a normocytic, normochromic anemia. Although the anemia is well tolerated by most patients and usually reverses completely within several months of stopping therapy, it may be problematic in patients with preexisting anemia. Intravenous therapy with amphotericin B should be administered cautiously in anemic patients or those predisposed to anemia. Frequent monitoring of blood counts and hemoglobin concentrations are recommended.

The amoxicillin in Amoxil has a moderate potential interaction with Diabetes Mellitus.

High urine concentrations of ampicillin may result in false-positive reactions when testing for the presence of glucose in urine using Clinitest®, Benedict's Solution or Fehling's Solution. Since this effect may also occur with amoxicillin, it is recommended that glucose tests based on enzymatic glucose oxidase reactions (such as Clinistix®) be used.

amphotericin B has a moderate potential interaction with Electrolyte Abnormalities.

Intravenously administered amphotericin B is nephrotoxic and may commonly cause hypo- or hyperkalemia, hypomagnesemia, and hypocalcemia secondary to renal impairment. Renal function and serum electrolytes should be closely monitored in all patients receiving intravenous therapy with amphotericin B, but in particular, those with preexisting renal and/or electrolyte abnormalities. Mineral and electrolyte supplementation is frequently required. Complications of electrolyte imbalances include muscle weakness, tetany, seizures and cardiac disturbances. Amphotericin B-related electrolyte abnormalities generally improve following cessation of therapy but may persist long after because of the drug's long terminal elimination half-life.

The amoxicillin in Amoxil has a moderate potential interaction with Hemodialysis.

Penicillin antibiotics (except for agents in the penicillinase-resistant class) are removed by hemodialysis. Doses should either be scheduled for administration after dialysis or supplemental doses be given after dialysis.

amphotericin B has a moderate potential interaction with Hyperkalemia.

Intravenously administered amphotericin B is nephrotoxic and may commonly cause hypo- or hyperkalemia, hypomagnesemia, and hypocalcemia secondary to renal impairment. Renal function and serum electrolytes should be closely monitored in all patients receiving intravenous therapy with amphotericin B, but in particular, those with preexisting renal and/or electrolyte abnormalities. Mineral and electrolyte supplementation is frequently required. Complications of electrolyte imbalances include muscle weakness, tetany, seizures and cardiac disturbances. Amphotericin B-related electrolyte abnormalities generally improve following cessation of therapy but may persist long after because of the drug's long terminal elimination half-life.

amphotericin B has a moderate potential interaction with Hypocalcemia.

Intravenously administered amphotericin B is nephrotoxic and may commonly cause hypo- or hyperkalemia, hypomagnesemia, and hypocalcemia secondary to renal impairment. Renal function and serum electrolytes should be closely monitored in all patients receiving intravenous therapy with amphotericin B, but in particular, those with preexisting renal and/or electrolyte abnormalities. Mineral and electrolyte supplementation is frequently required. Complications of electrolyte imbalances include muscle weakness, tetany, seizures and cardiac disturbances. Amphotericin B-related electrolyte abnormalities generally improve following cessation of therapy but may persist long after because of the drug's long terminal elimination half-life.

amphotericin B has a moderate potential interaction with Hypokalemia.

Intravenously administered amphotericin B is nephrotoxic and may commonly cause hypo- or hyperkalemia, hypomagnesemia, and hypocalcemia secondary to renal impairment. Renal function and serum electrolytes should be closely monitored in all patients receiving intravenous therapy with amphotericin B, but in particular, those with preexisting renal and/or electrolyte abnormalities. Mineral and electrolyte supplementation is frequently required. Complications of electrolyte imbalances include muscle weakness, tetany, seizures and cardiac disturbances. Amphotericin B-related electrolyte abnormalities generally improve following cessation of therapy but may persist long after because of the drug's long terminal elimination half-life.

amphotericin B has a moderate potential interaction with Magnesium Imbalance.

Intravenously administered amphotericin B is nephrotoxic and may commonly cause hypo- or hyperkalemia, hypomagnesemia, and hypocalcemia secondary to renal impairment. Renal function and serum electrolytes should be closely monitored in all patients receiving intravenous therapy with amphotericin B, but in particular, those with preexisting renal and/or electrolyte abnormalities. Mineral and electrolyte supplementation is frequently required. Complications of electrolyte imbalances include muscle weakness, tetany, seizures and cardiac disturbances. Amphotericin B-related electrolyte abnormalities generally improve following cessation of therapy but may persist long after because of the drug's long terminal elimination half-life.

The amoxicillin in Amoxil has a moderate potential interaction with Mononucleosis.

Patients with mononucleosis treated with an aminopenicillin antibiotic, may develop a pruritic erythematous maculopapular skin rash. The rash is usually self-limiting and resolves within days of discontinuing the offending agent. An altered drug metabolism or an immune-mediated process unrelated to drug hypersensitivity has been proposed as the underlying mechanism. Therapy with aminopenicillin antibiotics should not be administered in patients with mononucleosis.

The amoxicillin in Amoxil has a major potential interaction with Noninfectious Colitis.

Clostridioides difficile-associated diarrhea (CDAD), formerly pseudomembranous colitis, has been reported with almost all antibacterial drugs and may range from mild diarrhea to fatal colitis. The most common culprits include clindamycin and lincomycin. Antibacterial therapy alters the normal flora of the colon, leading to overgrowth of C difficile, whose toxins A and B contribute to CDAD development. Morbidity and mortality are increased with hypertoxin-producing strains of C difficile; these infections can be resistant to antimicrobial therapy and may require colectomy. CDAD must be considered in all patients who present with diarrhea after antibacterial use. Since CDAD has been reported to occur more than 2 months after antibacterial use, careful medical history is necessary. Therapy with broad-spectrum antibacterials and other agents with significant antibacterial activity should be administered cautiously in patients with history of gastrointestinal disease, particularly colitis; pseudomembranous colitis (generally characterized by severe, persistent diarrhea and severe abdominal cramps, and sometimes associated with the passage of blood and mucus), if it occurs, may be more severe in these patients and may be associated with flares in underlying disease activity. Antibacterial drugs not directed against C difficile may need to be stopped if CDAD is suspected or confirmed. Appropriate fluid and electrolyte management, protein supplementation, antibacterial treatment of C difficile, and surgical evaluation should be started as clinically indicated.

The amoxicillin in Amoxil has a moderate potential interaction with Phenylketonuria.

Some amoxicillin chewable tablets and suspensions products contain phenylalanine. The phenylalanine content should be considered when these products are used in patients who must restrict their intake of phenylalanine (i.e. phenylketonurics).

The amoxicillin in Amoxil has a moderate potential interaction with Renal Dysfunction.

Most beta-lactam antibiotics are eliminated by the kidney as unchanged drug and, in some cases, also as metabolites. The serum concentrations of beta-lactam antibiotics and their metabolites may be increased and the half-lives prolonged in patients with impaired renal function. Dosage adjustments may be necessary and modifications should be based on the degree of renal impairment as well as severity of infection in accordance with the individual product package labeling. Renal function tests should be performed periodically during prolonged and/or high-dose therapy, since nephrotoxicity and alterations in renal function have occasionally been associated with the use of these drugs.

amphotericin B has a moderate potential interaction with Renal Dysfunction.

Intravenously administered amphotericin B is nephrotoxic and may commonly cause decreased renal function and abnormalities including azotemia, hypo- and hyperkalemia, hypomagnesemia, hyposthenuria, renal tubular acidosis, and nephrocalcinosis. Renal function should be closely monitored in all patients receiving intravenous therapy with amphotericin B but in particular, patients with preexisting renal impairment. Dosage reductions are recommended. Serum creatinine, BUN, potassium and magnesium levels should be evaluated frequently, and dosing adjusted or discontinued accordingly.